AgeX Therapeutics, Inc. Business Finance Contracts & Agreements
52 Contracts & Agreements
- Contribution Agreements (1 contract)
- Exchange Agreements (1)
- Facility Agreements (4)
- Guaranty Agreements (2)
- Joinder Agreements (2)
- Loan Agreements (3)
- Note Agreements (14)
- Pledge Agreements (2)
- Registration Rights Agreements (5)
- Security Agreements (2)
- Stock Agreements (6)
- Subordination Agreement (1)
- Warrant Agreements (9)
- Form of Stock Option Agreement (Filed With SEC on April 1, 2024)
- Serina Therapeutics, Inc. 2017 Stock Option Plan (Filed With SEC on April 1, 2024)
- Asset Contribution Agreement dated March 26, 2024 between AgeX Therapeutics, Inc. and UniverXome Bioengineering, Inc (Filed With SEC on April 1, 2024)
- Agreement with respect to Convertible Notes dated March 26, 2024, among AgeX Therapeutics, Inc., UniverXome Bioengineering, Inc., the Subsidiary Obligors and Juvenescence Limited (Filed With SEC on April 1, 2024)
- Allonge and Seventh Amendment to Amended and Restated Convertible Promissory Notes dated March 26, 2024, among AgeX Therapeutics, Inc., the Guarantors party thereto and... (Filed With SEC on April 1, 2024)
- Warrant Agreement, dated March 19, 2024 between AgeX Therapeutics, Inc. and Equinity Trust Company, LLC (Filed With SEC on March 22, 2024)
- Form of Post-Merger Warrant included in Warrant Agreement dated March 19, 2024 (Filed With SEC on March 22, 2024)
- Sixth Amendment to Amended and Restated Convertible Promissory Note, dated February 9, 2024, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 14, 2024)
- Joinder Agreement, dated November 9, 2023, between Reverse Bioengineering, Inc., ReCyte Therapeutics, Inc., UniverXome Bioengineering, Inc., AgeX Therapeutics, Inc. and... (Filed With SEC on November 14, 2023)
- Guaranty Agreement, dated November 9, 2023, between Reverse Bioengineering, Inc., ReCyte Therapeutics, Inc., UniverXome Bioengineering, Inc. and Juvenescence Limited (Filed With SEC on November 14, 2023)
- Form of Pledge Agreement by AgeX Therapeutics, Inc (Filed With SEC on November 14, 2023)
- Allonge and Fifth Amendment to Amended and Restated Convertible Promissory Note, dated November 9, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on November 14, 2023)
- Joinder Agreement, dated November 9, 2023, between Reverse Bioengineering, Inc., ReCyte Therapeutics, Inc., UniverXome Bioengineering, Inc., AgeX Therapeutics, Inc. and... (Filed With SEC on November 14, 2023)
- Guaranty Agreement, dated November 9, 2023, between Reverse Bioengineering, Inc., ReCyte Therapeutics, Inc., UniverXome Bioengineering, Inc. and Juvenescence Limited (Filed With SEC on November 14, 2023)
- Form of Pledge Agreement by AgeX Therapeutics, Inc (Filed With SEC on November 14, 2023)
- Allonge and Fifth Amendment to Amended and Restated Convertible Promissory Note, dated November 9, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on November 14, 2023)
- Amended and Restated Certificate of Designation of Series B Preferred Stock (Filed With SEC on November 14, 2023)
- Amended and Restated Certificate of Designation of Series A Preferred Stock (Filed With SEC on November 14, 2023)
- Amendment to Secured Convertible Promissory Note, executed by AgeX Therapeutics, Inc. and Juvenescence Limited on July 31, 2023 (Filed With SEC on August 4, 2023)
- Fourth Amendment to Amended and Restated Secured Convertible Promissory Note, executed by AgeX Therapeutics, Inc. and Juvenescence Limited on July 31, 2023 (Filed With SEC on August 4, 2023)
- Registration Rights Agreement, dated July 21, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on July 21, 2023)
- Exchange Agreement, dated July 21, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on July 21, 2023)
- Form of Certificate of Designation of Series B Preferred Stock (Filed With SEC on July 21, 2023)
- Form of Certificate of Designation of Series A Preferred Stock (Filed With SEC on July 21, 2023)
- Third Amendment to Amended and Restated Secured Convertible Promissory Note, dated June 2, 2023, executed by AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on June 8, 2023)
- Allonge and Second Amendment to Amended and Restated Convertible Promissory Note dated May 9, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on May 12, 2023)
- Third Amendment to that certain Secured Convertible Facility Agreement, dated March 30, 2020, by and between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on March 15, 2023)
- Subordination Agreement, dated March 15, 2023, between AgeX Therapeutics, Inc., Serina Therapeutics, Inc. and the other investors signatory thereto (Filed With SEC on March 15, 2023)
- Convertible Promissory Note, dated March 15, 2023, between AgeX Therapeutics, Inc. and Serina Therapeutics, Inc (Filed With SEC on March 15, 2023)
- Convertible Note Purchase Agreement, dated March 15, 2023, between AgeX Therapeutics, Inc. and Serina Therapeutics, Inc (Filed With SEC on March 15, 2023)
- Amended and Restated Security Agreement, dated March 13, 2023, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on March 15, 2023)
- Secured Convertible Promissory Note dated March 13, 2023, executed by AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on March 15, 2023)
- Amended and Restated Secured Convertible Promissory Note, dated February 9, 2023, executed by AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 10, 2023)
- Amendment No. 3 to Registration Rights Agreement, dated February 14, 2022, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 15, 2022)
- Warrant Agreement, dated February 14, 2022, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 15, 2022)
- Security Agreement, dated February 14, 2022, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 15, 2022)
- Secured Note dated February 14, 2022, executed by AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 15, 2022)
- Form of Warrant (Filed With SEC on February 15, 2022)
- Amendment No. 2 to Loan Facility Agreement, dated November 8, 2021, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on November 9, 2021)
- Amendment No. 2 to Registration Rights Agreement, dated February 10, 2021, between AgeX Therapeutics, Inc. and Juvenescence Limited (Filed With SEC on February 11, 2021)